摘要
阿尔茨海默病(阿尔茨海默病)是一种最常见的神经退行性疾病,其特征是海马和大脑皮质中淀粉样-β(Aβ)肽的聚集。炎症被认为是AD的认知功能下降的发展驱动力的炎症反应过程中,激活的星形胶质细胞和小胶质细胞诱导的Aβ肽产生促炎因子和毒素,促进AD脑部神经退行性疾病、老年痴呆症。因此,抑制胶质细胞过度激活在广告大脑可能会导致治疗效果。雷公藤甲素,从中药雷公藤中提取的一种天然化合物,具有抗炎作用。雷公藤内酯醇对AD样是否具有通过抗炎作用病理的预防作用尚不清楚。目前的研究表明,腹腔注射雷公藤甲素(20μg/kg)15周显著减轻学习和记忆缺陷问题,并在AD转基因小鼠脑阻止Aβ积累(APP/PS1小鼠)。这些结果都伴随着对APP/PS1小鼠雷公藤内酯醇相比APP/PS1小鼠生理盐水治疗脑胶质细胞的激活和炎症因子含量减少。此外,我们观察到有丝分裂原活化蛋白激酶(MAPK p38、ERK和JNK)磷酸化也在APP/PS1小鼠大脑中的雷公藤甲素治疗抑制。总之,我们的研究表明,分子机制研究雷公藤甲素对AD模型的治疗作用可能是通过抑制蛋白激酶活性的抑制炎症反应。
关键词: 阿尔茨海默病、ERK、JNK、p38、炎症、雷公藤内酯醇。
Current Alzheimer Research
Title:Triptolide Rescues Spatial Memory Deficits and Amyloid-β Aggregation Accompanied by Inhibition of Inflammatory Responses and MAPKs Activity in APP/PS1 Transgenic Mice
Volume: 13 Issue: 3
Author(s): Yan-Qiu Cui, Qi Wang, Dong-Mei Zhang, Jun-Ya Wang, Bing Xiao, Yan Zheng, Xiao-Min Wang
Affiliation:
关键词: 阿尔茨海默病、ERK、JNK、p38、炎症、雷公藤内酯醇。
摘要: Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease characterized by aggregation of amyloid-β (Aβ) peptide in the hippocampus and cortex of brain. Neuroinflammation is considered a driving force of the progression of cognitive decline in AD. During the neuroinflammatory process, activated astrocytes and microglia induced by Aβ peptide produce pro-inflammatory factors and neurotoxins, which promote neurodegeneration in AD brain, eventually dementia. Thus, the suppression of glial over-activation in AD brain might result in therapeutic effect. Triptolide, a natural compound extracted from the Chinese medicinal herb Tripterygium wilfordii Hook F., has shown anti-inflammatory effects. Whether triptolide exhibits preventive effects on AD-like pathology via anti-inflammatory action is unclear. The present study showed that intraperitoneal injection of triptolide (20 μg/kg) for 15 weeks markedly alleviated deficits in learning and memory, and prevented Aβ accumulation in the brain of AD transgenic mice (APP/PS1 mice). These results were accompanied by reduction in glial activation and contents of pro-inflammatory factors in the brain of APP/PS1 mice treated by triptolide compared to saline-treated APP/PS1 mice. In addition, we observed that the Mitogen-activated protein kinases (MAPKs, including p38, ERK and JNK) phosphorylation was also suppressed by treatment of triptolide in the brain of APP/PS1 mice. Taken together, our study suggests that molecular mechanisms underlying the therapeutic effects of triptolide on the AD model might involve inhibition of the neuroinflammation by suppressing MAPKs activity.
Export Options
About this article
Cite this article as:
Yan-Qiu Cui, Qi Wang, Dong-Mei Zhang, Jun-Ya Wang, Bing Xiao, Yan Zheng, Xiao-Min Wang , Triptolide Rescues Spatial Memory Deficits and Amyloid-β Aggregation Accompanied by Inhibition of Inflammatory Responses and MAPKs Activity in APP/PS1 Transgenic Mice, Current Alzheimer Research 2016; 13 (3) . https://dx.doi.org/10.2174/156720501303160217122803
DOI https://dx.doi.org/10.2174/156720501303160217122803 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
WISP1 (CCN4) Autoregulates its Expression and Nuclear Trafficking of β-Catenin during Oxidant Stress with Limited Effects upon Neuronal Autophagy
Current Neurovascular Research Vitamin D and Stroke: Promise for Prevention and Better Outcome
Current Vascular Pharmacology Role of the Endocannabinoid System in the Neuroendocrine Responses to Inflammation
Current Pharmaceutical Design “Bedside-to-Bench” Behavioral Outcomes in Animal Models of Pain: Beyond the Evaluation of Reflexes
Current Neuropharmacology Metabotropic Glutamate Receptor Dependent Cortical Plasticity in Chronic Pain
Current Neuropharmacology Malignant Mesothelioma Resistance to Apoptosis: Recent Discoveries and their Implication for Effective Therapeutic Strategies
Current Medicinal Chemistry Expression, Distribution and Regulation of Phosphodiesterase 5
Current Pharmaceutical Design Sertraline Associated with REM Sleep Behavior Disorder: A Case Report
Current Psychopharmacology Autoantibodies in Autoimmune Diseases
Current Pharmaceutical Design Therapeutic Implications for Immunophilin Ligands in the Treatment of Neurodegenerative Diseases
Current Drug Targets - CNS & Neurological Disorders Amyloid-β Peptides, Alzheimer's Disease and the Blood-brain Barrier
Current Alzheimer Research Hypoxia-Inducible Factor-1α Contributes to Brain Edema after Stroke by Regulating Aquaporins and Glycerol Distribution in Brain
Current Neurovascular Research Relevant Modulation by Ferrous Ions of N-Methyl-D-Aspartate Receptors in Ischemic Brain Injuries
Current Neurovascular Research <i>Uncaria rhynchophylla</i> and its Major Constituents on Central Nervous System: A Review on Their Pharmacological Actions
Current Vascular Pharmacology VIP-induced Neuroprotection of the Developing Brain
Current Pharmaceutical Design Advancing Drug Therapy for Brain Tumours: A Current Review of the Pro-inflammatory Peptide Substance P and its Antagonists as Anti-cancer Agents
Recent Patents on CNS Drug Discovery (Discontinued) Neurotrophins in the Lower Urinary Tract: Becoming of Age
Current Neuropharmacology Transdermal Oxandrolone: Ex Vivo Percutaneous Absorption Study
Current Drug Delivery The Endocannabinoid System and Multiple Sclerosis
Current Pharmaceutical Design Herbal Compounds with Special Reference to Gastrodin as Potential Therapeutic Agents for Microglia Mediated Neuroinflammation
Current Medicinal Chemistry